These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
253 related articles for article (PubMed ID: 12450705)
21. Vaccines safety; effect of supervision or SMS on reporting rates of adverse events following immunization (AEFI) with meningitis vaccine (MenAfriVac™): a randomized controlled trial. Ateudjieu J; Stoll B; Nguefack-Tsague G; Tchangou C; Genton B Vaccine; 2014 Sep; 32(43):5662-8. PubMed ID: 25160064 [TBL] [Abstract][Full Text] [Related]
22. Capacity for a global vaccine safety system: the perspective of national regulatory authorities. Graham JE; Borda-Rodriguez A; Huzair F; Zinck E Vaccine; 2012 Jul; 30(33):4953-9. PubMed ID: 22658930 [TBL] [Abstract][Full Text] [Related]
25. Active surveillance of adverse events following childhood immunization in Singapore. Thoon KC; Soh SB; Liew WK; Gunachandran A; Tan NW; Chong CY; Yung CF Vaccine; 2014 Sep; 32(39):5000-5. PubMed ID: 25045811 [TBL] [Abstract][Full Text] [Related]
26. Vaccine safety monitoring systems in developing countries: an example of the Vietnam model. Ali M; Rath B; Thiem VD Curr Drug Saf; 2015; 10(1):60-7. PubMed ID: 25859677 [TBL] [Abstract][Full Text] [Related]
27. Evaluation of 'SAEFVIC', A Pharmacovigilance Surveillance Scheme for the Spontaneous Reporting of Adverse Events Following Immunisation in Victoria, Australia. Clothier HJ; Crawford NW; Russell M; Kelly H; Buttery JP Drug Saf; 2017 Jun; 40(6):483-495. PubMed ID: 28342074 [TBL] [Abstract][Full Text] [Related]
28. Improving global monitoring of vaccine safety: a survey of national centres participating in the WHO Programme for International Drug Monitoring. Letourneau M; Wells G; Walop W; Duclos P Drug Saf; 2008; 31(5):389-98. PubMed ID: 18422379 [TBL] [Abstract][Full Text] [Related]
30. Systematic review of reporting rates of adverse events following immunization: an international comparison of post-marketing surveillance programs with reference to China. Guo B; Page A; Wang H; Taylor R; McIntyre P Vaccine; 2013 Jan; 31(4):603-17. PubMed ID: 23200940 [TBL] [Abstract][Full Text] [Related]
31. Thrombosis with thrombocytopenia syndrome (TTS) and vaccine-induced immune thrombocytopenia and thrombosis (VITT): Brighton Collaboration case definitions and guidelines for data collection, analysis, and presentation of immunisation safety data. Schönborn L; Pavord S; Chen VMY; Pai M; Gwarzo DH; Buttery J; Munoz FM; Tran H; Greinacher A; Law B Vaccine; 2024 Mar; 42(7):1799-1811. PubMed ID: 38302339 [TBL] [Abstract][Full Text] [Related]
32. Surveillance for adverse events following immunization (AEFI) for 7 years using a computerised vaccination system. Alguacil-Ramos AM; Muelas-Tirado J; Garrigues-Pelufo TM; Portero-Alonso A; Diez-Domingo J; Pastor-Villalba E; Lluch-Rodrigo JA Public Health; 2016 Jun; 135():66-74. PubMed ID: 26976484 [TBL] [Abstract][Full Text] [Related]
33. Respiratory distress in the neonate: Case definition & guidelines for data collection, analysis, and presentation of maternal immunization safety data. Sweet LR; Keech C; Klein NP; Marshall HS; Tagbo BN; Quine D; Kaur P; Tikhonov I; Nisar MI; Kochhar S; Muñoz FM; Vaccine; 2017 Dec; 35(48 Pt A):6506-6517. PubMed ID: 29150056 [No Abstract] [Full Text] [Related]
34. Annual report: Surveillance of adverse events following immunisation in Australia, 2011. Mahajan D; Cook J; Dey A; Macartney K; Menzies RI Commun Dis Intell Q Rep; 2012 Dec; 36(4):E315-32. PubMed ID: 23330706 [TBL] [Abstract][Full Text] [Related]
35. [Surveillance system for adverse events following immunization against yellow fever in Burkina Faso in 2008. Good practice recommendations]. Yaméogo TM; Breugelmans JG; Kambou JL; Badolo O; Tiendrebéogo S; Traoré E; Avokey F; Yactayo S Med Trop (Mars); 2009 Aug; 69(4):320-1. PubMed ID: 19725376 [TBL] [Abstract][Full Text] [Related]
36. Adverse events following immunization: real causality and myths. Principi N; Esposito S Expert Opin Drug Saf; 2016 Jun; 15(6):825-35. PubMed ID: 26986067 [TBL] [Abstract][Full Text] [Related]
37. Surveillance of adverse events following immunisation: the model of SAEFVIC, Victoria. Clothier HJ; Crawford NW; Kempe A; Buttery JP Commun Dis Intell Q Rep; 2011 Dec; 35(4):294-8. PubMed ID: 22624490 [TBL] [Abstract][Full Text] [Related]
38. Surveillance of adverse effects following vaccination and safety of immunization programs. Waldman EA; Luhm KR; Monteiro SA; Freitas FR Rev Saude Publica; 2011 Feb; 45(1):173-84. PubMed ID: 21181055 [TBL] [Abstract][Full Text] [Related]
39. Adverse events following immunization: is this time for the use of WHO causality assessment? Tafuri S; Gallone MS; Calabrese G; Germinario C Expert Rev Vaccines; 2015 May; 14(5):625-7. PubMed ID: 25805053 [TBL] [Abstract][Full Text] [Related]
40. Acute aseptic arthritis: Case definition & guidelines for data collection, analysis, and presentation of immunisation safety data. Woerner A; Pourmalek F; Panozzo C; Pileggi G; Hudson M; Caric A; Abraham S; Varricchio F; Velasco C; Oleske J; Bauwens J; Bonhoeffer J; Vaccine; 2019 Jan; 37(2):384-391. PubMed ID: 30342899 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]